Replies to post #120713 on Biotech Values

[masterlongevity]

good question.
the carrier population had a high incidence of an SAE called vasogenic edema, after which doses are held, and they possibly thought this interfered with ability to detect difference. same size was also reasonably small.

i don't have a good answer. that's why i think the odds of success are pretty low in this population in mild to moderate AD. However, I do think if they treated carriers earlier in the disease, say prodromal or MCI, bapineuzumab would have a good chance of working.

[genisi]

Perhaps because ApoE4 genotype prevalence among AD patients in north EU and USA is around 60% and they hope that if they start the anti-Aß therapy early - before the ß-amyloid plaque burden is too heavy, it might improve the patient's state.